Progress of hematopoietic stem cell transplantation for treatment of multiple myeloma in the era of novel agents

VernacularTitle:新药时代造血干细胞移植治疗多发性骨髓瘤研究进展
Author: Jie LI
Keywords: Multiple myeloma; Hematopoietic stem cell transplantation; Drugs; investigational
From: Journal of Leukemia & Lymphoma 2017;26(8):505-508
CountryChina
Language:Chinese
Abstract: Hematopoietic stem cell transplantation (HSCT) has become the frontline therapy for patients with multiple myeloma (MM), and for young patients with primary MM, early autologous stem cell transplantation (ASCT) is a standard treatment. In the era of novel drugs, the application of new pharmaceutics in the consolidation and maintenance therapy before and after HSCT can improve the efficacy of HSCT. The novel agents pose a challenge to the status of HSCT in relapsed and refractory myeloma. This article summarizes the recent clinical studies of HSCT in the era of novel agents to clarify the role of HSCT in treatment of MM.